Patents by Inventor Richard Esmond BEATSON

Richard Esmond BEATSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GAMMADELTA T CELL EXPANSION PROCEDURE
    Publication number: 20230323298
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Application
    Filed: January 23, 2023
    Publication date: October 12, 2023
    Inventors: John MAHER, Ana Catarina, Richard Esmond BEATSON
  • ?? T cell expansion procedure
    Patent number: 11566222
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 31, 2023
    Assignee: KING'S COLLEGE LONDON
    Inventors: John Maher, Ana Catarina Parente Pereira Puri, Richard Esmond Beatson
  • GAMMADELTA T CELL EXPANSION PROCEDURE
    Publication number: 20200140816
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Application
    Filed: December 18, 2019
    Publication date: May 7, 2020
    Inventors: John MAHER, Ana Catarina PARENTE PEREIRA PURI, Richard Esmond BEATSON
  • GAMMADELTA T CELL EXPANSION PROCEDURE
    Publication number: 20200123502
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Inventors: John MAHER, Ana Catarina PARENTE PEREIRA PURI, Richard Esmond BEATSON
  • Gammadelta T cell expansion procedure
    Patent number: 10557117
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 11, 2020
    Assignee: King's College London
    Inventors: John Maher, Ana Catarina Parente Pereira Puri, Richard Esmond Beatson
  • METHODS AND COMPOSITIONS FOR TREATING CANCER WITH SIGLEC-9 ACTIVITY MODULATORS
    Publication number: 20190211099
    Abstract: The invention provides methods and compositions for treating Siglec-9 mediated cancer in a subject, where the cells of the cancer express sialylated Core-1-MUC1 glycoproteins that engage with Siglec-9 expressed on certain immune cells, for example, monocytes and macrophages of the subject. Prior to treatment, the cancerous cells may evade the immune system of the host by binding Siglec-9 expressed by the immune cells, whereupon binding activates a number of pro-tumorigenic, Siglec-9 mediated activities in or via the immune cells. However, when treated with an inhibitor of Siglec-9 activity, the Siglec-mediated activities can be mitigated and the host immune system can recognize and elicit an immune response against the cancer cells expressing the sialylated Core-1 MUC1 glycoproteins.
    Type: Application
    Filed: June 30, 2017
    Publication date: July 11, 2019
    Inventors: Joy Marilyn BURCHELL, Richard Esmond BEATSON
  • GAMMADELTA T CELL EXPANSION PROCEDURE
    Publication number: 20170342381
    Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.
    Type: Application
    Filed: December 4, 2015
    Publication date: November 30, 2017
    Inventors: John MAHER, Ana Catarina PARENTE PEREIRA PURI, Richard Esmond BEATSON